Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
New Brunswick, NJ
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Nashville, TN
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Dallas, TX
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Houston, TX
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
San Antonio, TX
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated:  2/11/2016
GSK Investigational Site
mi
from
Salt Lake City, UT
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795
Status: Enrolling
Updated: 2/11/2016
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation
A Novel Immunotherapy for Liver Transplant Patients With Hepatocellular Carcinoma: Anti-tumor Effect of IL2-activated Donor Liver Natural Killer Cell
Status: Enrolling
Updated:  2/11/2016
University of Miami
mi
from
Miami, FL
Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation
A Novel Immunotherapy for Liver Transplant Patients With Hepatocellular Carcinoma: Anti-tumor Effect of IL2-activated Donor Liver Natural Killer Cell
Status: Enrolling
Updated: 2/11/2016
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  2/11/2016
Massachusetts General Hospital Mass General 2
mi
from
Boston, MA
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 2/11/2016
Massachusetts General Hospital Mass General 2
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  2/11/2016
University of Texas/MD Anderson Cancer Center MD Anderson PSC
mi
from
Houston, TX
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 2/11/2016
University of Texas/MD Anderson Cancer Center MD Anderson PSC
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  2/11/2016
Novartis Investigative Site
mi
from
Parkville,
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 2/11/2016
Novartis Investigative Site
mi
from
Parkville,
Click here to add this to my saved trials
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Status: Enrolling
Updated:  2/11/2016
Oregon Health & Science University OHSU 3
mi
from
Portland, OR
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Status: Enrolling
Updated: 2/11/2016
Oregon Health & Science University OHSU 3
mi
from
Portland, OR
Click here to add this to my saved trials
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Status: Enrolling
Updated:  2/11/2016
University of Utah / Huntsman Cancer Institute Huntman 2
mi
from
Salt Lake City, UT
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Status: Enrolling
Updated: 2/11/2016
University of Utah / Huntsman Cancer Institute Huntman 2
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Status: Enrolling
Updated:  2/11/2016
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4
mi
from
Tampa, FL
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Status: Enrolling
Updated: 2/11/2016
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4
mi
from
Tampa, FL
Click here to add this to my saved trials
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Status: Enrolling
Updated:  2/11/2016
Novartis Investigative Site
mi
from
Edmonton,
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Status: Enrolling
Updated: 2/11/2016
Novartis Investigative Site
mi
from
Edmonton,
Click here to add this to my saved trials
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy With or Without Chemotherapy for High Risk Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  2/11/2016
CDH Proton Center
mi
from
Warrenville, IL
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy With or Without Chemotherapy for High Risk Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 2/11/2016
CDH Proton Center
mi
from
Warrenville, IL
Click here to add this to my saved trials
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy With or Without Chemotherapy for High Risk Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  2/11/2016
ProCure Proton Therapy Center
mi
from
Oklahoma City, OK
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy With or Without Chemotherapy for High Risk Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 2/11/2016
ProCure Proton Therapy Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy With or Without Chemotherapy for High Risk Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  2/11/2016
Hampton University Proton Therapy Institute
mi
from
Hampton, VA
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy With or Without Chemotherapy for High Risk Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 2/11/2016
Hampton University Proton Therapy Institute
mi
from
Hampton, VA
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
University of Chicago
mi
from
Chicago, IL
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
Bodyaesthetic
mi
from
St. Louis, MO
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
Bodyaesthetic
mi
from
St. Louis, MO
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
Aesthetic Plastic Surgery
mi
from
Great Neck, NY
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
Aesthetic Plastic Surgery
mi
from
Great Neck, NY
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
Columbia University
mi
from
New York, NY
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
New York Group
mi
from
Tarrytown, NY
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
New York Group
mi
from
Tarrytown, NY
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
UT Southwestern
mi
from
Dallas, TX
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
UT Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated:  2/11/2016
Northwestern University
mi
from
Chicago, IL
Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy
Status: Enrolling
Updated: 2/11/2016
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC
A Phase II, Single Arm, Open-label, Multicenter, Study of Oral LGX818 in Patients With BRAF V600 Mutant, Advanced Non-small Cell Lung Cancer (NSCLC) That Have Progressed During or After at Least One Prior Chemotherapy
Status: Enrolling
Updated:  2/11/2016
University of Chicago Medical Center SC - 2
mi
from
Chicago, IL
Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC
A Phase II, Single Arm, Open-label, Multicenter, Study of Oral LGX818 in Patients With BRAF V600 Mutant, Advanced Non-small Cell Lung Cancer (NSCLC) That Have Progressed During or After at Least One Prior Chemotherapy
Status: Enrolling
Updated: 2/11/2016
University of Chicago Medical Center SC - 2
mi
from
Chicago, IL
Click here to add this to my saved trials
Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
Phase I Trial Of Intratumoral EGFR Antisense DNA And DC-Chol Liposomes In Advanced Oral Squamous Cell Carcinoma
Status: Enrolling
Updated:  2/11/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
Phase I Trial Of Intratumoral EGFR Antisense DNA And DC-Chol Liposomes In Advanced Oral Squamous Cell Carcinoma
Status: Enrolling
Updated: 2/11/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
Phase I/II Study of Neoadjuvant Weekly Docetaxel and Mitoxantrone Prior to Prostatectomy in Patients With High Risk Localized Prostate Cancer
Status: Enrolling
Updated:  2/11/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
Phase I/II Study of Neoadjuvant Weekly Docetaxel and Mitoxantrone Prior to Prostatectomy in Patients With High Risk Localized Prostate Cancer
Status: Enrolling
Updated: 2/11/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
Phase I/II Study of Neoadjuvant Weekly Docetaxel and Mitoxantrone Prior to Prostatectomy in Patients With High Risk Localized Prostate Cancer
Status: Enrolling
Updated:  2/11/2016
Portland VA Medical Center
mi
from
Portland, OR
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
Phase I/II Study of Neoadjuvant Weekly Docetaxel and Mitoxantrone Prior to Prostatectomy in Patients With High Risk Localized Prostate Cancer
Status: Enrolling
Updated: 2/11/2016
Portland VA Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Trastuzumab (Herceptin) With Docetaxel (Taxotere), Carboplatin and Trastuzumab (Herceptin) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification
Status: Enrolling
Updated:  2/11/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Trastuzumab (Herceptin) With Docetaxel (Taxotere), Carboplatin and Trastuzumab (Herceptin) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification
Status: Enrolling
Updated: 2/11/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Malignant Pleural Effusion With ZD6474
Treatment of Malignant Pleural Effusion With ZD6474, a Novel Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  2/11/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Malignant Pleural Effusion With ZD6474
Treatment of Malignant Pleural Effusion With ZD6474, a Novel Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 2/11/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant
Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/11/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant
Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/11/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Detroit, MI
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
New York, NY
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Tacoma, WA
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated:  2/12/2016
mi
from
Edegem,
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction
Status: Enrolling
Updated: 2/12/2016
mi
from
Edegem,
Click here to add this to my saved trials
Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers
Pilot Study of the Role of 11-dh-TXB2 in Prostate Cancer Screening and Diagnosis
Status: Enrolling
Updated:  2/12/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers
Pilot Study of the Role of 11-dh-TXB2 in Prostate Cancer Screening and Diagnosis
Status: Enrolling
Updated: 2/12/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
Proton Stereotactic Body Radiation Therapy (SBRT) for Medically Inoperable, Peripheral Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Pilot Study
Status: Enrolling
Updated:  2/12/2016
Massachusetts General Hospital
mi
from
Boston, MA
Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
Proton Stereotactic Body Radiation Therapy (SBRT) for Medically Inoperable, Peripheral Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Pilot Study
Status: Enrolling
Updated: 2/12/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer
A Phase I Trial of Hypofractionated Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/12/2016
Massachusetts General Hospital
mi
from
Boston, MA
Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer
A Phase I Trial of Hypofractionated Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/12/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer
Does Blocking Proinflammatory Cytokines Diminish Cancer-Related Fatigue?
Status: Enrolling
Updated:  2/12/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer
Does Blocking Proinflammatory Cytokines Diminish Cancer-Related Fatigue?
Status: Enrolling
Updated: 2/12/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation
Status: Enrolling
Updated:  2/12/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation
Status: Enrolling
Updated: 2/12/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/12/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/12/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/12/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/12/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
Treatment of Stage IV Breast Cancer With Activated T Cells After Peripheral Blood Stem Cell Transplant (Pilot Phase II)
Status: Enrolling
Updated:  2/15/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
Treatment of Stage IV Breast Cancer With Activated T Cells After Peripheral Blood Stem Cell Transplant (Pilot Phase II)
Status: Enrolling
Updated: 2/15/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Combined Colon and Endometrial Cancer Screening in Women With HNPCC
A Pilot Study for Combined Colon and Endometrial Cancer Screening in Women at High-Risk for Colon and Endometrial Cancer
Status: Enrolling
Updated:  2/15/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Combined Colon and Endometrial Cancer Screening in Women With HNPCC
A Pilot Study for Combined Colon and Endometrial Cancer Screening in Women at High-Risk for Colon and Endometrial Cancer
Status: Enrolling
Updated: 2/15/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating
Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating
Status: Enrolling
Updated:  2/15/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating
Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating
Status: Enrolling
Updated: 2/15/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Lapatinib and Bortezomib in Patients With Advanced Malignancies
A Phase I Study of the HER1, HER2 Dual Kinase Inhibitor, Lapatinib Plus the Proteosomal Inhibitor Bortezomib in Patients With Advanced Malignancies
Status: Enrolling
Updated:  2/15/2016
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Lapatinib and Bortezomib in Patients With Advanced Malignancies
A Phase I Study of the HER1, HER2 Dual Kinase Inhibitor, Lapatinib Plus the Proteosomal Inhibitor Bortezomib in Patients With Advanced Malignancies
Status: Enrolling
Updated: 2/15/2016
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A Phase I Trial of the Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Status: Enrolling
Updated:  2/15/2016
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A Phase I Trial of the Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Status: Enrolling
Updated: 2/15/2016
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials